Homburger advised ADC Therapeutics, a commercial-stage biotechnology company producing antibody drug conjugates (ADCs) for cancer patients, on its 13.4 m of common shares, and, to certain investors who so choose in lieu of common shares, pre-funded
Advestra advised Cactus life sciences, a global scientific communications agency that works with blue chip pharma and biotechnology companies, on nspm and eluSCIdate’
Niederer Kraft Frey (NKF) advised Moving Spine on the funding received to further develop improving standards of care for patients with spinal injuries. NKF’s team Corporate/M&A counsel Thomas Sprecher (pictured right)
Novartis AG, the Swiss multinational pharmaceutical corporation based in Basel, has appointed Alejandro Bes (pictured) as its global head of legal for the Immunology business unit. The lawyer steps into the role as his predecessor,
VISCHER has advised DomoHealth SA on all corporate and contractual issues related to this financing round. The team was led by Maxime Chollet (partner, Corporate/M&A) with Basile Walder (managing associate, Corporate/M&
Niederer Kraft Frey advised MediCrops on the acquisition of a majority stake in Hygieia Partners (TopPharm pharmacy) and Topmed (Topmed medical office). MediCrops, which is based in Pfäffikon, was founded in 2018 and is a
Niederer Kraft Frey advised Calibre Scientific on the acquisition of Bioreba, a Swiss biotech company and provider of plant pathogen diagnostic test kits and services, selling to diagnostic labs, universities, public and private research institutions
In a recent LinkedIn announcement, Andrea Ferrari (pictured) revealed his new role as the Global Head of Compliance and Corporate Legal at Sandoz, marking a significant milestone in his career. The move comes after the
Bär & Karrer advises Miele o the Establishment of a Joint Venture in the Fields of Infection Control and Life Science Miele and Metall Zug have reached an agreement outlining the establishment of a
In a resounding success, Lonza has secured its financial future by placing two tranches totaling CHF 400 million. The first tranche of CHF 185 million, featuring a 2.25% interest rate and maturing in 2028, was complemented by a second
